SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No.____)
Pharma-Bio Serv, Inc.
-----------------------------------------------------
(Name of Issuer)
Common Stock, $.0001 par value ("the shares")
--------------------------------------------------------
(Title of Class of Securities)
0001304161
----------------------------------------------------------
(CUSIP Number)
David Selengut, Esq. at Ellenoff Grossman & Schole LLP
370 Lexington Avenue NY NY 10017 212-370-1300
------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
May 8, 2006
-----------------------------------------------------------
(Date of Event which Requires FIling of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b) (3) or (4), check the following box [ ].
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 6 pages
CUSIP No. 0001304161 13D Page 2 of 6 pages
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Venturetek, LP
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [x ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 Source of Funds
See Item #3 herein. (PF)
-------------------------------------------------------------------------------
5 Check Box if Disclosure of Legal Proceedings is required pursuant to
Items 2(d) or 2(e)
-------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES 4,697,990
BENEFICIALLY --------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH 0
REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 4,697,990
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,697,990
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
23.63%
-------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
CUSIP No. 0001304161 13D Page 3 of 6 pages
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
David Selengut
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [X ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 Source of Funds
See Item #3 herein. (PF)
-------------------------------------------------------------------------------
5 Check Box if Disclosure of Legal Proceedings is required pursuant to
Items 2(d) or 2(e)
-------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES 4,697,990
BENEFICIALLY --------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH 0
REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 4,697,990
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,697,990
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
23.63%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
--------------------------------------------------------------------------------
*SEE,INSTRUCTIONS BEFORE FILLING OUT
Page 4 of 6 pages
Item 1. (a) Security of Issuer:
Pharma-Bio Serv, Inc.
Common Stock, $0001 par value
Address of Issuer's Principal Executive Offices:
373 Mendez Vigo, Suite 110
Dorado, Puerto Rico 00646
Item 2. (a) Name of Person Filing:
Venturetek, LP and David Selengut ("Mr. Selengut") ("The
Reporting Parties"). See Exhibit A for a copy of their agreement
to file this statement on behalf of each of them.
(b) Address of Principal Business Office or if None, Residence:
The Reporting Parties business address is 370 Lexington
Avenue, New York, NY 10017.
(c) Citizen:
Venturetek, LP is a Delaware Limited Partnership and Mr.
Selengut is a citizen of the United States.
(d) Common Stock, $.0001 par value
(e) CUSIP #
0001304161
Item 3. Source and amount of funds or Other Consideration
Venturetek used $2,000,000 of its funds to purchase
the shares and warrants.
Item 4. Purpose of Transaction
The purpose of this transaction was for investment. None of
the Reporting Parties have any plans or proposals that would
relate or result in changing or influencing the control of the
Issuer, or in any of the following:
(a) The acquisition by any person of additional securities of the
issuer, or the disposition of securities of the issuer, or in any
of the following:
(b) An extraordinary corporate transaction, such as a merger,
reorganization or liquidation, involving the Issuer or any of its
subsidiaries;
(c) A sale or transfer of a material amount of assets of the issuer
or any of its subsidiaries;
(d) Any change in the present board of directors or management of the
Issuer, including any plans or proposals to change the number or
terms of directors or to fill any existing vacancies on the
board;
(e) Any material change in the present capitalization or dividend
policy of the Issuer;
(f) Any other material change in the issuer's business or corporate
structure including but not limited to, if the issuer is a
registered closed-end investment company, an plans or proposals
to make anyu cahnges in its investment policy for which a vote is
required by section 13 of the Investment Company Act of 1940;
(g) Changes in the Issuer's charter, by-laws or instruments
corresponding thereto or other actions which may impede the
acquisition of control of the Issuer by any person;
(h) Causing a class of securities of the Issuer to be delisted from a
national securities exchange or to cease to be authorized to be
quoted in an inter-dealer quotation system of a registered
national securities association;
(i) A class of equity securities of the Issuer becoming eligible for
termination of registration pursuant to Section 12(g)(4) of the
Act; or
(j) Any action similar to any of those enumerated above.
Page 5 of 6 pages
Item 5. Ownership:
(a) As of May 8, 2006, Venturtek may be deemed to beneficially own
4,697,990 shares or 23.6% of the Issuer, consisting of 3,132,932
shares of common stock and warrants to purchase 1,565,058 shares
of common stock held by Venturetek, LP.
(b) As of May 8, 2006, Mr. Selengut may be deemed to beneficially own
4,697,990 shares or 23.6% of the Issuer held by Venturetek (1).
(c) There were no other purchase in the past sixty days.
Item 6. Contracts, Arrangements, Understandings, or Relationships with Respect
to Securities of the Issuer:
None
Item 7. Material to be Filed as Exhibits.
---------------------------------
Exhibit A - Agreement between Venturetek and Mr. Selengut to file
this Statement on 13d on behalf of each of them.
____________________________
(1) Mr. Selengut is the sole member of the General Partner of Venturetek, LP.
Mr. Selengut disclaims beneficial ownership in such shares.
Signature
After reasonable inquiry and to the best or our knowledge and belief, we certify
that the information set forth in this statement is true, complete and correct.
Date: May 15, 2006
Venturetek, LP
By: Taurus Max LLC, GP
/s/ David Selengut
__________________________
David Selengut
Member
/s/ David Selengut
Date: May 15, 2006 By: ___________________________
David Selengut